- Home
- AIRT vs IMMX Comparison
AIRT vs IMMX Comparison
Compare AIRT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- IMMX
- Stock Information
- Founded
- AIRT 1980
- IMMX 2014
- Country
- AIRT United States
- IMMX United States
- Employees
- AIRT N/A
- IMMX N/A
- Industry
- AIRT Air Freight/Delivery Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- AIRT Consumer Discretionary
- IMMX Health Care
- Exchange
- AIRT Nasdaq
- IMMX Nasdaq
- Market Cap
- AIRT 53.2M
- IMMX 61.1M
- IPO Year
- AIRT N/A
- IMMX 2021
- Fundamental
- Price
- AIRT $22.48
- IMMX $2.13
- Analyst Decision
- AIRT
- IMMX Strong Buy
- Analyst Count
- AIRT 0
- IMMX 1
- Target Price
- AIRT N/A
- IMMX $7.00
- AVG Volume (30 Days)
- AIRT 1.1K
- IMMX 261.4K
- Earning Date
- AIRT 06-27-2025
- IMMX 08-11-2025
- Dividend Yield
- AIRT N/A
- IMMX N/A
- EPS Growth
- AIRT N/A
- IMMX N/A
- EPS
- AIRT N/A
- IMMX N/A
- Revenue
- AIRT $291,850,000.00
- IMMX N/A
- Revenue This Year
- AIRT N/A
- IMMX N/A
- Revenue Next Year
- AIRT N/A
- IMMX N/A
- P/E Ratio
- AIRT N/A
- IMMX N/A
- Revenue Growth
- AIRT 1.75
- IMMX N/A
- 52 Week Low
- AIRT $14.56
- IMMX $1.26
- 52 Week High
- AIRT $30.60
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- AIRT 61.08
- IMMX 52.67
- Support Level
- AIRT $18.86
- IMMX $2.16
- Resistance Level
- AIRT $24.92
- IMMX $2.46
- Average True Range (ATR)
- AIRT 0.91
- IMMX 0.17
- MACD
- AIRT -0.03
- IMMX -0.02
- Stochastic Oscillator
- AIRT 65.92
- IMMX 27.33
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.